Trevena, Inc. (TRVN) Granted Key U.S. Method Of Use Patent For TRV027
8/5/2014 10:08:09 AM
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,796,204, “Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof,” which covers methods of use for TRV027, including a method of treating acute heart failure. The patent is expected to provide coverage for methods of use for TRV027 until at least 2029. Corresponding patent applications are pending in major markets throughout the world. TRV027 is an investigational peptide drug currently being studied in the BLAST-AHF Phase 2b trial for the treatment of acute heart failure (AHF).
Help employers find you! Check out all the jobs and post your resume.
comments powered by